Pharming Group N.V. announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA.

Pharming Group N.V. confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period ended March 31, on Thursday, May 8, 2025.

For media and investors only

Pharming Group N.V. announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”).

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of April:

Pharming Group N.V. announces that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency (CVID) patients with immune dysregulation.

Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2024.

Pharming Group N.V. announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of March:

Pharming Group N.V. confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended December 31, on Thursday, March 13, 2025.